SecBot SecBot
Biotech Drug Report Generated Aug 21, 2026

Sandostatin

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved
Time to market
Already marketed, approved since 1988 (Sandostatin) and 1998 (Sandostatin LAR)
Why 2/10
No hard, dated catalyst is scheduled in the next ~12 months: Sandostatin was approved in 1988 and Sandostatin LAR in 1998, both decisions passed decades ago, and the drug is a small legacy product within a ~$57B-revenue company, so impactScore stays at 2.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

Treat Sandostatin as immaterial to NVS: it is an approved, generics-eroded legacy drug with no scheduled binary catalyst, so it should not drive a trade. For anyone holding NVS, the stock's move will be set by the broader pipeline and earnings (consensus rating 'hold', mean price target $157.15 vs. ~$156.24 spot, per local analyst data), not by this product.

Price Chart

Loading chart...

Executive Summary

Sandostatin (octreotide, marketed with the long-acting depot form Sandostatin LAR) is a decades-old somatostatin-analog drug from Novartis (NYSE: NVS) used to treat acromegaly and symptoms of neuroendocrine/carcinoid tumors. It is fully approved and commercialized, FDA approval catalysts are recorded locally for Sandostatin (1988-10-21) and Sandostatin LAR (1998-11-25), and is a mature, generic-eroded legacy product rather than a growth or binary-catalyst asset.

How It Works

Octreotide is a synthetic copy of somatostatin, a natural hormone that tells the body to slow down secretion of growth hormone and several digestive hormones. By mimicking somatostatin, it blocks excess hormone production, which is why it is used to treat acromegaly (excess growth hormone) and to control flushing/diarrhea and tumor hormone output in neuroendocrine and carcinoid tumors. Sandostatin LAR is a slow-release depot version given by injection about once a month instead of several times a day.

Trial Status

No active Novartis development on Sandostatin itself: local trial records show a Novartis Phase 3 in diabetic retinopathy (NCT00248157) was terminated in 2006 for "inconsistent treatment benefit," and an investigator-led Phase 3 combining Sandostatin LAR with axitinib in non-pancreatic neuroendocrine tumors (NCT01744249) is COMPLETED. The main competitive development is a next-generation octreotide subcutaneous depot (CAM2029) whose Phase 3 acromegaly trial (NCT04076462) is COMPLETED.

The Two-Sided Case

▲ Bull Case3
Long-proven franchise: local FDA catalyst records show approvals in 1988 (Sandostatin) and 1998 (Sandostatin LAR), giving ~35 years of clinical track record as a standard-of-care in acromegaly and neuroendocrine tumors.
Generic supply disruption could temporarily favor the brand: FDA recall actions in 2026 show Teva's generic octreotide acetate LAR (ANDA210317) was pulled in multiple Class II recalls over lack of sterility assurance, which can create branded-demand spillover.
Negligible downside to NVS: with 2026 consensus revenue near $57.6B (local analyst estimates), Sandostatin is a minor legacy line, and the drug's erosion does not threaten the company's thesis.
▼ Bear Case4
Mature, generic-eroded franchise: Teva's octreotide acetate is an approved generic of Sandostatin LAR (ANDA210317), and multiple additional generic entrants historically pressure branded sales, classic late-lifecycle revenue decline.
No pipeline catalyst: Novartis's own octreotide program outside approved indications was terminated (diabetic retinopathy Phase 3 stopped for 'inconsistent treatment benefit'), and Sandostatin has no pending regulatory action or label expansion.
Competitive headwinds: newer somatostatin analogues and a next-generation octreotide depot (CAM2029) with a completed Phase 3 in acromegaly (NCT04076462) compete for the same patients.
Stock-level context is mixed-to-cautious: local 13F data show large trims/exits in NVS (Goldman Sachs -54.3%, Dodge & Cox near-exit -89.1%, Optiver exit) in Q2-2026, and the local bull/bear checklist flags a high short-volume ratio (0.44 on 2026-08-20), though these are company-wide, not drug-specific.

Upcoming Catalysts

  • None scheduled for Sandostatin itself, no PDUFA, readout, or label decision in the next 12 months.
  • NVS quarterly earnings: watch legacy-portfolio sales trends (Sandostatin erosion) as a minor line item.
  • Competitor next-gen octreotide depot (CAM2029) commercialization/regulatory steps in acromegaly, which would further pressure the category.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov